Web of Science: 16 citations, Scopus: 20 citations, Google Scholar: citations,
Advances and unmet needs in genetic, basic and clinical science in Alport syndrome : report from the 2015 International Workshop on Alport Syndrome
Gross, Oliver (University Medicine Goettingen (Germany))
Kashtan, Clifford E. (University of Minnesota Medical School (USA))
Rheault, Michelle N. (University of Minnesota Medical School (USA))
Flinter, Frances (Guy's and St Thomas' NHS Foundation Trust (United Kingdom))
Savige, Judith (The University of Melbourne (Australia))
Miner, Jeffrey H. (Washington University School of Medicine (USA))
Torra, Roser (Institut d'Investigació Biomèdica Sant Pau)
Ars, Elisabet (Institut d'Investigació Biomèdica Sant Pau)
Deltas, Constantinos (University of Cyprus)
Savva, Isavella (University of Cyprus)
Perin, Laura (University of Southern California, Children's Hospital Los Angeles (USA))
Renieri, Alessandra (University of Siena (Italy))
Ariani, Francesca (University of Siena (Italy))
Mari, Francesca (University of Siena (Italy))
Baigent, Colin (University of Oxford (United Kingdom))
Judge, Parminder (University of Oxford (United Kingdom))
Knebelman, Bertrand (Université Paris Descartes (France))
Heidet, Laurence (Clinique Maurice Lamy, Hôpital Necker-Enfants Malades (France))
Lagas, Sharon (Alport Syndrome Foundation (USA))
Blatt, Dave (Alport Foundation of Australia)
Ding, Jie (Peking University First Hospital (China))
Zhang, Yanqin (Peking University First Hospital (China))
Gale, Daniel P. (University College London-Centre for Nephrology (United Kingdom))
Prunotto, Marco (F. Hoffmann-La Roche Ltd. Roche Pharma Research & Early Development (Switzerland))
Xue, Yong (Global Clinical Development. Sanofi Genzyme (The Netherlands))
Schachter, Asher D. (Novartis Institutes for BioMedical Research (USA))
Morton, Lori C.G. (Regeneron Pharmaceuticals (USA))
Blem, Jacqui (Regulus Therapeutics (USA))
Huang, Michael (Regulus Therapeutics (USA))
Liu, Shiguang (Sanofi-Genzyme R&D Center (USA))
Vallee, Sebastien (Discovery Biology. Shire (USA))
Renault, Daniel (FEDERG (Belgium))
Schifter, Julia (Alport Israel)
Skelding, Jules (Alport UK (United Kingdom))
Gear, Susie (Alport UK (United Kingdom))
Friede, Tim (University Medical Center Goettingen (Germany))
Turner, A. Neil (University of Edinburgh (United Kingdom))
Lennon, Rachel (University of Manchester (United Kingdom))
Universitat Autònoma de Barcelona

Date: 2017
Abstract: Alport syndrome (AS) is a genetic disease characterized by haematuric glomerulopathy variably associated with hearing loss and anterior lenticonus. It is caused by mutations in the COL4A3, COL4A4 or COL4A5 genes encoding the α3α4α5(IV) collagen heterotrimer. AS is rare, but it accounts for >1% of patients receiving renal replacement therapy. Angiotensin-converting enzyme inhibition slows, but does not stop, the progression to renal failure; therefore, there is an urgent requirement to expand and intensify research towards discovering new therapeutic targets and new therapies. The 2015 International Workshop on Alport Syndrome targeted unmet needs in basic science, genetics and diagnosis, clinical research and current clinical care. In three intensive days, more than 100 international experts including physicians, geneticists, researchers from academia and industry, and patient representatives from all over the world participated in panel discussions and breakout groups. This report summarizes the most important priority areas including (i) understanding the crucial role of podocyte protection and regeneration, (ii) targeting mutations by new molecular techniques for new animal models and potential gene therapy, (iii) creating optimal interaction between nephrologists and geneticists for early diagnosis, (iv) establishing standards for mutation screening and databases, (v) improving widespread accessibility to current standards of clinical care, (vi) improving collaboration with the pharmaceutical/biotech industry to investigate new therapies, (vii) research in hearing loss as a huge unmet need in Alport patients and (viii) the need to evaluate the risk and benefit of novel (including 'repurposing') therapies on an international basis.
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès.
Document: article ; recerca ; publishedVersion
Subject: Alport syndrome ; Chronic kidney disease ; Guidelines ; Hereditary kidney disease ; Nephroprotection
Published in: Nephrology Dialysis Transplantation, Vol. 32, Issue 6 (June 2017) , p. 916-924, ISSN 1460-2385

PMID: 27190345
DOI: 10.1093/ndt/gfw095

9 p, 1.5 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (scientific output) > Health sciences and biosciences > Institut d'Investigació Biomèdica Sant Pau
Articles > Research articles
Articles > Published articles

 Record created 2018-03-26, last modified 2019-06-28

   Favorit i Compartir